SCHEMBL18148264

SCHEMBL18148264

CCNC(=O)NC1CCC(Nc2ncc3ccc(=O)n(C(C)C)c3n2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 15/20 1.00
▸ MAPK10 P53779 13/20 1.00
▸ MAPK9 P45984 11/20 1.00
▸ CDK2 P24941 4/20 0.61
▸ CDK4 P11802 3/20 0.61
▸ CCND1 P24385 3/20 0.61
▸ CCNT1 O60563 2/20 0.61
▸ CCNE1 P24864 2/20 0.61
▸ CDK9 P50750 2/20 0.61
▸ CDK6 Q00534 2/20 0.61
▸ CCNK O75909 2/20 0.56
▸ CCNA2 P20248 2/20 0.56
▸ CDK7 P50613 2/20 0.56
▸ CCNH P51946 2/20 0.56
▸ MNAT1 P51948 2/20 0.56
▸ CDK12 Q9NYV4 2/20 0.56
▸ CCND2 P30279 1/20 0.51
▸ CCND3 P30281 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16802577 1.00 MAPK8 (1.00) MAPK8MAPK10MAPK9CDK2CDK4
SCHEMBL16802770 1.00 MAPK8 (1.00) MAPK8MAPK10MAPK9CDK2CDK4
SCHEMBL18148271 0.88 MAPK8 (1.00) MAPK8MAPK10MAPK9CDK2CDK4
SCHEMBL16802780 0.88 MAPK8 (1.00) MAPK8MAPK10MAPK9CDK2CDK4
SCHEMBL16802613 0.87 MAPK8 (0.77) MAPK8MAPK10MAPK9CDK2CDK4
SCHEMBL18148248 0.86 MAPK8 (1.00) MAPK8MAPK10MAPK9CDK2CDK4
SCHEMBL16802705 0.86 MAPK8 (1.00) MAPK8MAPK10MAPK9CDK2CDK4
SCHEMBL16802782 0.86 MAPK8 (1.00) MAPK8MAPK10MAPK9CDK2CDK4
SCHEMBL16802707 0.85 MAPK8 (1.00) MAPK8MAPK10MAPK9CDK2CDK4
SCHEMBL18148266 0.83 MAPK8 (1.00) MAPK8MAPK10MAPK9CDK2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160304466-A1 NOVEL COMPOUNDS AS JNK KINASE INHIBITORS THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY 2016-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160304466-A1 NOVEL COMPOUNDS AS JNK KINASE INHIBITORS MAPK3, MAP3K3, MAP3K2 MAPK8 55/4885MAPK10 31/4885MAPK9 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback